Clear, defensible intended purpose drives evidence requirements, claims, and classification. Getting it right early prevents non-conformities, rework, and regulatory delays.

ICE enables real-time, catheter-based cardiac imaging that supports minimally invasive interventions in congenital and structural heart disease. Its growing use reflects a shift toward precision-guided, lower-risk procedures in interventional cardiology.

Validated finite element analysis can reduce physical testing in medical device development, but it rarely replaces it entirely. Regulatory confidence depends on rigorous verification, validation, and a clearly defined context of use. The strongest submissions integrate FEA with targeted physical…

Brain–computer interfaces (BCIs) are emerging as powerful tools for restoring movement, communication, and neurological function, but widespread clinical adoption is limited by safety, regulatory, cybersecurity, and long-term reliability challenges. For manufacturers, early integration of risk management and regulatory compliance is…

Key considerations for launching a medical device in the US, UK or EU, covering market size, regulatory pathways, timelines, and strategic benefits to help manufacturers choose the best first-entry market.

Medical-grade plastics are essential in healthcare for their safety, biocompatibility, and cost-effectiveness, but their single-use nature creates major environmental and health concerns. Biobased alternatives and small behavioural changes, like reducing unnecessary device use, can significantly cut waste and carbon emissions.

AI is transforming MedTech but brings new risks in bias, safety, and security. The EU AI Act raises the bar for oversight of high-risk AI systems. ISO/IEC 42001 provides a certifiable framework for responsible AI governance - covering ethics, risk,…

WHOOP’s FDA warning shows how wellness features can trigger medical device regulation. If your product estimates clinical metrics, disclaimers aren’t enough. Design, language, and outputs define regulatory risk. DiGA and FDA frameworks offer different paths, but both demand clarity and…

Test Labs returned to MEDICA with a new approach: driving to Germany, joining the UK Pavilion, and actively engaging across both MEDICA and COMPAMED. Strong footfall, valuable client meetings, and early-stage innovation conversations made the event commercially productive. The trip…

Evidence is the critical factor that turns promising medtech concepts into adoptable, scalable innovations. While early enthusiasm is common, real progress depends on validating clinical need, demonstrating benefits, and generating robust biological, operational, and commercial evidence.

Orthopaedic device startups operate in a high-stakes market shaped by strict regulations, cost pressures, and cautious multinationals. Success depends on surgeon collaboration, early reimbursement planning, strong clinical data, and building a compelling value story. With careful exit timing, often just…

Many medical devices fail because they weren’t designed for commercial reality. Early design decisions lock in manufacturing complexity, validation burden, cost structures, and scalability long before regulatory approval.

MedTech’s innovation problem is a lack of collaboration. To accelerate progress, the industry must move beyond siloed R&D and embrace radical partnerships across companies, regulators, and clinicians. The organisations that build collaboration into their DNA will lead not only in…

AI is reshaping Alzheimer’s detection by enabling earlier, faster, and less invasive diagnosis. By combining advanced neuroimaging analysis, speech and cognitive monitoring, and emerging blood-based biomarkers, AI-powered medtech tools can identify subtle preclinical changes years before symptoms appear. While challenges…